University of Zurich[UZH]

cabmm
center for applied biotechnology and molecular medicine

Newsletter

Another milestone for regulatory affairs at the CABMM

Dear CABMM members

We made another milestone for the prosperity of our CABMM: **the Musculoskeletal Research Unit (MSRU) will be officially accredited for GLP** (Good Laboratory Practice) through the Swissmedic very soon. The inspection at the beginning of April went well and accreditation was already guaranteed. Only a few minor amendments still have to be made. All members of the MSRU had been working very hard over the last few years to prepare for the inspection with appropriate documentation related to standard operative procedures (SOPs), and IT as well as general archiving and administration issues. This was made possible mainly due to the efforts of our staff, doctors Sabine Koch, Katja Nuss and Karina Klein, as well as our chief technician, Ladina Ferguson Ettinger, in combination with our external and ever patient GLP consultant, Iris Wüthrich, – a huge "thank you" to all of them and also to all other co-workers of the MSRU.

What does this mean?

It means that preclinical studies can now be performed under GLP conditions required by the FDA and/or the European Medicines Agency (EMEA) for having new medical products registered for human use or entering human clinical trials. This is an important step for translation in medicine to bring an innovation from bench to bedside or from basic science to the patient.

It also means that the CABMM in conjunction with the medical faculty (MeF) and University Hospital Zurich (USZ) is the first and only European University where all three accreditation levels for the registration of medical products are available: Good Laboratory Practice (GLP) for preclinical studies at the MSRU, Good Manufacturing Practice (GMP) for biological and other products at the Swiss Center for Regenerative Medicine (SCRM, Prof. Hoerstrup) and finally Good Clinical Practice (GCP) at the University Hospital (USZ), where a diligent team is responsible for administrating clinical trials in human patients for clinical phases I-III. Therefore, this means that industrial partners can conduct their research in collaboration with their academic partners from the UZH/ETHZ from the bench to the bedside with all investigations situated under one roof.

The three-level accreditation also means that CABMM members can – or should - include the major issues of regulatory affairs into their portfolio of translational medicine. After all, what's the use of developing sophisticated products meant for human use when they are unable to make it through registration? Or fail to generate sufficient interest from industrial partners and investment companies because of regulatory issues, thus impeding further development, such as up-scaling for industrial production.

Furthermore, the implemented three-level accreditation will also allow for the appropriate planning and contacting of research groups right from the start of a project. Therefore, CABMM members can profit from this portfolio immediately by having preclinical studies or manufacturing issues scheduled appropriately, thereby preventing unnecessary loss of time and money. Please take advantage of this situation at the CABMM and help us in making this platform even more successful!

Translational Research Board

That brings me to the Translational Research Board (TLRB), our future think tank for translation from bench to bedside, where basic researchers, industrial partners and clinicians will meet to shape a better research and clinical future. A future, where research results are not hindered by regulatory issues or where novel products just disappear into a draw never to be seen again after initial positive results. After lengthy discussions, we have the guidelines ready to go and we are now in the phase of recruiting members from industry. We will also have three positions in the TLRB open for CABMM members from clinics, basic or applied research. So if you are interested in participating, please indicate your interest to our managing director, Dr. Silke Kalchofner-Mark, by sending her a short e-mail including your CV until the end of June 2014. We are looking forward to another new step and to having more members involved in shaping the translational future of the CABMM.

CABMM Plenary Meeting and Spring Seminar

And that brings me to my last call – the participation in our general membership assembly and the subsequent CABMM Spring Seminar. I would like to see all of our members there, and hopefully for the Spring Seminar, many of your graduate/postgraduate students as well. It is THE platform, where members can meet and exchange new ideas, find new partners for research projects, and also profit from the diverse expertise throughout the CABMM. Don't forget, it is a platform to see new things, which otherwise would have gone unnoticed, since they may not be directly related to your field or otherwise have escaped your attention. Take the chance to meet other members and exchange ideas during coffee breaks or at our Apéro at the end of the day. I am looking forward to seeing you all!

Prof. Dr. med. vet. Brigitte von Rechenberg, Dipl. ECVS
Chair CABMM Steering Committee

Announcements

Upcoming event:
The **7th CABMM Plenary Meeting** and the **4th CABMM Spring Seminar** will take place on **May 16th, 2014**. Don't miss this event and register now! Further information and registration at http://www.cabmm.uzh.ch/Events-2.html.

Call for information:
Please inform us about your CABMM-affiliated publications, awards, career development and any other **information related to the CABMM**, so we can continue to keep our records up-to-date. Thank you!

University of Zurich[UZH]

New members

Prof. Dr. Jeffrey Bode, Laboratory of Organic Chemistry, ETH Zurich.
The Bode group develops novel chemical reactions for the synthesis of organic molecules under physiological conditions, e.g. in water and in the presence of proteins, living cells, and tissues. Their application includes wound healing, drug delivery, cellular encapsulation, and artificial tissues.

Prof. Dr. Martin Flück, Departement of Orthopedics, Balgrist University Hospital, Zurich.
The research group of Prof. Flück investigates the mechanisms that are responsible for plasticity of the muscular system in response to altered use and injury, specifically muscle degeneration with unloading after tendon rupture and muscle rehabilitation subsequent to orthopedic surgery.

Prof. Dr. Isabel Wanke, Interventional Work Research, Neuroradiology - SwissNeuroInstitute, Klinik Hirslanden, Zurich.
The Interventional Work Research Group is interested in diagnosis and minimally invasive treatment options in neurovascular diseases. The current focus is on neurovascular wall pathologies, i.e. on intracranial aneurysms and neurovascular aspects of dementia.

Congratulations

Inaugural lecture:
PD Dr. Peter J. Richards, Scientific Director of the CABMM, gave his inaugural lecture entitled "Stem cells and bone loss: what's the link?". Congratulations, Pete!

Honorary membership:
At the end of January 2014, **Prof. Dr. Ulrich Hübscher**, director of the Institute for Veterinary Biochemistry and Molecular Biology (IVBMB) and former dean of the Vetsuisse Faculty Zurich, took leave and retired. Ueli was one of the first CABMM members and a driving force in its creation. We would like to thank him for all the efforts that he put into the CABMM and are very happy to announce that he was awarded CABMM honorary membership. Thank you, Ueli!

New position:
We congratulate **Prof. Dr. Dr. Michael O. Hottiger**, vice president of the CABMM Steering Committee, on being the successor of Prof. Ueli Hübscher and wish him all the best for his new position as director of the Institute for Veterinary Biochemistry and Molecular Biology (IVBMB).

Press / Publications

"Stem cells and bone loss"
About the research of Peter J. Richards.
Horizon 2020 Projects: Portal, Preview:58-61, 2014.

"From bench to bedside and back again"
About the CABMM.
Horizon 2020 Projects: Portal, 1:96-97, 2014.

"CABMM: Cartilage repair and regeneration"
About the research of Brigitte von Rechenberg.
Horizon 2020 Projects: Online publication, April 2014.
http://horizon2020projects.com/special-reports/cabmm-cartilage-repair-and-regeneration/

"Not lost in translation"
About the CABMM.
PanEuropeanNetworks: Science&Technology, 10:224-225, March 2014.

"Enzyme linked to age-related bone disease"
About the research of Peter J. Richards.
Projects magazine 33:50-51, 2013.

Delivery of BMP-2 by two clinically available apatite materials: In vitro and in vivo comparison. Hänseler P,1 Ehrbar M, Kruse K, Fischer E, Schibli R, Ghayor C, Weber FE *J Biomed Mater Res A* 2014 (Epub ahead of print).

"Transcatheter Implantation of Homologous "Off-the-Shelf" Tissue-Engineered Heart Valves With Self-Repair Capacity" Driessen-Mol A, Emmert MY, Dijkman PE, Frese L, Sanders B, Weber B, Cesarovic N, Sidler M, Leenders J, Jenni R, Grünenfelder J, Falk V, Baaijens FPT, Hoerstrup, SP. *J Am Coll Cardiol* 2014;63(13): 1320-9.

"Influence of non-steroidal anti-inflammatory drugs (NSAIDs) on osseointegration of dental implants in rabbit calvaria. " Cai WX, Ma L, Zheng LW, Kruse-Gujer A, Stübinger S, Lang NP, Zwahlen RA *Clin Oral Implants Res*. 2014 (Epub ahead of print).

"Regenerative therapies for equine degenerative joint disease: a preliminary study" Broeckx S, Zimmermann M, Crocetti S, Suls M, Marien T, Ferguson SJ, Chiers K, Duchateau L, Franco-Obregon A, Wuertz K, Spaas JH. *PLoS One* 2014;9(1):e85917.

"A new-generation, low-permeability flow diverting device for treatment of saccular aneurysms" Mallik AS, Nuss K, Kronen PW, Klein K, Karol A, von Rechenberg B, Rüfenacht DA, Wanke I, Kulcsar Z *Eur Radiol* 2014;24(1):12-8,.

"Artd1/Parp1 regulates reprogramming by transcriptional regulation of Fgf4 via Sox2 ADP-ribosylation" Weber FA, Bartolomei G, Hottiger MO, Cinelli P. *Stem Cells* 2013;31(11): 2364-73.

"Influence of altitude on vitamin D and bone metabolism of lactating sheep and goats" Kohler M, Leiber F, Willems H, Merbold L, Liesegang A. *J Anim Sci* 2013;91(11):5259-68.

"Ultrastructural Characteristics of Sheep and Horse Mesenchymal Stem Cells (MSCs)" Ozen A, Gul Sancak I, von Rechenberg B, Koch S. *Microscopy Research*, 2013;1(3):17-23.

CABMM
University of Zurich
Winterthurerstrasse 190
8057 Zurich
www.cabmm.uzh.ch

cabmm
center for applied biotechnology and molecular medicine